Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab vs Sorafenib for Unresectable HCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (IMbrave150): An Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2021 May 27;[EPub Ahead of Print], PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu, TY Kim, M Kudo, V Breder, P Merle, A Kaseb, D Li, S Mulla, W Verret, DZ Xu, S Hernandez, B Ding, J Liu, C Huang, HY Lim, AL Cheng, M DucreuxFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.